Loading...
•
Mar 31, 2020
Iovance Q1 2020 Earnings Report
Iovance reported first quarter 2020 financial results and provided a corporate update.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $69.6 million, or $0.55 per share, for the first quarter ended March 31, 2020. The company held $251.2 million in cash, cash equivalents, short-term investments and restricted cash at the end of the quarter.
Continued progress toward commercializing Iovance TIL for melanoma and cervical cancer indications
COVID-19 impacted healthcare systems globally, but key business operations continued
First potential cell therapy in solid tumors and a broad TIL platform positions Iovance as a leader in TIL cell therapy for cancer
Completed dosing in the pivotal study in patients with metastatic melanoma and is currently conducting a pivotal study in patients with metastatic cervical cancer.
Forward Guidance
Iovance is making forward looking statements about the success, timing, projected enrollment, manufacturing and production capabilities, and cost of our ongoing clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...